Plant virus DNA constructs and virus resistant plants comprising said constructs

ABSTRACT

DNA constructs encoding an RNA molecule capable of interacting with an RNA dependent RNA polymerase encoded for by a virus when invading a plant such that either an eliciting element or a plus sense RNA is produced as a consequence of the interaction with the RNA dependent RNA polymerase encoded by the said invading virus, whereby any produced plus sense RNA molecule is capable of encoding for an eliciting element, plants containing such constructs and processes for obtaining such plants.

BACKGROUND

The present invention relates to pathogen resistant plants and in particular to pathogen resistant plants wherein pathogen resistance is triggered in response to invading pathogens such as viruses, DNA constructs for use in such plants and methods of introducing virus induced resistance into plants.

Viral infections in plants are frequently responsible for detrimental effects in growth, undesirable morphological changes, decreased yield and the like. Such infections often result in a higher susceptibility to infection in infected plants to other plant pathogens and plant pests.

Virus particles generally comprise a relatively small amount of genetic material (single or double stranded RNA or DNA) protected by a protein or proteins which in some viral types can also be surrounded with host-derived lipid membranes, yielding infectious particles. Viruses are dependent on host cells for multiplication and may therefore be regarded as intracellular parasites.

Plants have evolved a number of defensive mechanisms to limit the effects of viral infection. For example, so-called horizontal or partial resistances which are polygenic in nature and so-called vertical resistances which are monogenic in nature.

Horizontal resistance is difficult to introduce successfully into plants in breeding programs, however, vertical resistance can be bred into plants relatively easily within plant breeding programs. Genes coding for virus resistance can act constitutively in a passive sense, ie without a requirement for inducing gene expression. Constitutively expressed virus resistances include as modes of action non-host resistances, tolerance ie inhibition of disease establishment, immunity ie inhibition of transport or the presence of antiviral agents and the like. Alternatively, genes coding for virus resistance in plants can be actively switched on by way of inducing expression of a gene or genes encoding for a viral resistance. An example of such a system includes the hypersensitive response.

So-called hypersensitive responses (HSR) in plants have been reported and are generally characterized by death of plant cells in the vicinity of the penetrating pathogen shortly after infection. Movement of the pathogen through infected or invaded cells is restricted or blocked due to necrosis of the invaded cell and/or cells in the environs of the invaded cell(s). In addition, HSR involves a cascade of additional or secondary defense responses and the accumulation of certain proteins and secondary metabolites, leading to a general increased level of resistance to attack by pathogens. HSR reactions to invading organisms are generally thought to involve a resistance gene product in the plant cell which recognizes and interacts with an elicitor element, ie the product of an avirulence gene of a pathogen. Elicitor element recognition in the cells of a resistant plant triggers an HSR reaction which in its turn restricts the pathogen infection to a single cell or cells, or at most to a few plant cells in the immediate vicinity thereof.

An example of HSR-mediated resistance to virus infection is that of tobacco plants harbouring the N' resistance gene to tobamoviruses such as TMV and ToMV, which contain the coat protein avirulence gene. Thus far, more than twenty single dominant HSR-type resistance genes have been identified, and are present in many agronomically important crops including tobacco, tomato, potato, pepper, lettuce, and the like.

Despite the apparent abundance of resistance sources to certain viruses, many crops still lack effective resistance genes to important viral pathogens Fraser, R. S. S. (1992). Euphytica 63:175!. Searching of wild type germplasm collections has identified only a few suitable sources of viral resistance capable of being introduced successfully into agronomically important crops. An example is the absence of vertical resistance genes to cucumber mosaic virus (CMV) in many agronomically important crop types including but not limited to tomato, pepper, cucumber, melon, lettuce and the like.

Plant breeders continuously try to develop varieties of crop plant species tolerant to or resistant to specific virus strains. In the past, virus resistance conferring genes have been transferred from wild types related to commercial plants into commercial varieties through breeding. The transfer of an existing resistance in the wild from the wild type gene pool to a cultivar is a tedious process in which the resistance conferring gene(s) must first be identified in a source (donor) plant species and then combined into the gene pool of a commercial variety. Resistance or tolerance generated in this way is typically active only against one or at best a few strains of the virus in question. A further disadvantage is that the breeding programme generally takes a long time, measured in years, in getting to agronomically useful plants.

In an alternative, a system referred to as "cross-protection" has been employed. Cross-protection is a phenomenon in which infection of a plant with one strain of a virus protects that plant against superinfection with a second related virus strain. The cross-protection method preferentially involves the use of avirulent virus strains to infect plants, which act to inhibit a secondary infection with a virulent strain of the same virus. However, the use of a natural cross-protection system can have several disadvantages. The method is very labour intensive because it requires inoculation of each individual plant crop, and carries the risk that an avirulent strain may mutate to a virulent strain, thus becoming a causal agent for crop disease in itself. A further possible hazard is that an avirulent virus strain in one plant species can act as a virulent strain in another plant species.

Genetically engineered cross-protection is a form of virus resistance which phenotypically resembles natural cross-protection, but is achieved through the expression of genetic information of a viral coat protein from the genome of a genetically manipulated plant. It is known that expression of the tobacco mosaic virus strain U1 (TMV-U1) coat protein gene from the genome of a transgenic plant can result in a delay of symptom development after infection with any TMV strain. Similarly, coat protein-mediated protection has also been obtained for alfalfa mosaic virus (AMV), potato virus X (PVX) and cucumber mosaic virus (CMV). For some plant viruses, eg luteoviruses, it is difficult to obtain detectable amounts of the corresponding coat protein in a transgenic plant, and consequently, virus resistance is generally lowered. Furthermore, any alleged degree of protection requires that the plant produces coat protein continually and thus imposes an energy burden on the plant. As a result of such limitations the commercial value of such technology remains unclear.

A further example of genetically engineered virus resistance includes the introduction of plant viral satellite RNA wherein expression of incorporated genetic material modifies the plant virus or its effects.

An object of the present invention is to provide an alternative more reliable engineered virus resistance strategy in plants to those engineered resistances known in the art, based on direct pathogen induced expression of molecules in target tissues of a plant before the invading pathogen can establish itself in the host plant.

Another object of the invention is to combine genetic engineering plant transformation technology with naturally existing plant viral defense mechanisms in plant tissue.

DETAILED DESCRIPTION

According to the present invention there is provided a plant virus DNA construct capable of encoding directly or indirectly for a minus sense RNA molecule capable of interacting with an RNA dependent RNA polymerase encoded for by an invading virus such that at least one eliciting element is produced as a consequence of the interaction with the RNA dependent RNA polymerase encoded by the said invading virus.

In another embodiment of the invention there is provided a plant virus recombinant DNA construct capable of encoding for a plus sense RNA molecule capable of interacting with an RNA dependent RNA polymerase encoded for by an invading virus producing as a result of such interaction, a plus sense RNA molecule which is capable of encoding for at least one eliciting element capable of eliciting a natural plant defense in the plant on invasion of the plant by the said invading virus.

The plant virus DNA construct can be derived from any virus source capable of attacking a plant, however it is preferred that the plant virus DNA is derived from any virus source which is known to attack, is suspected of attacking or is capable of attacking an agronomically attractive plant type. It can be a natural plant virus DNA suitably modified for expression or it may be derived synthetically. The plant virus DNA should be capable of encoding for transcription into an RNA sequence complementary (ie minus sense) to a viral RNA (ie plus sense) in plant cells. In addition, the plant virus DNA should contain a portion or segment thereof which when transcribed to yield minus sense RNA and further transcribed to plus sense RNA, upon translation of the plus sense RNA, is capable of giving rise to at least one eliciting element or part thereof sufficient to elicit a natural plant defense mechanism against an invading virus. Suitable plant virus DNA or RNA sources are those derived from plant viruses capable of invading plant types such as tomatoes, peppers, melons, lettuces, cauliflowers, broccolis, cabbages, brussels sprouts, sugar beet, corn (maize), sweetcorn, onions, carrots, leeks, cucumbers, tobacco and the like. Also included as plant virus DNA or RNA sources are those derived from plant viruses capable of invading plant types from ornamental crops such as Impatiens, begonia, petunia, pelargoniums (geraniums, viola, cyclamen, verbena, vinca, tagetes, primula, saintpaulia and the like.

A minus sense RNA molecule is one which contains at least a cistron or part thereof corresponding to at least a portion of the said plant virus DNA and is capable of giving rise to a plus sense RNA molecule transcribable from the said minus sense RNA molecule which is capable of coding for and giving rise to at least one eliciting element or part thereof in plant cells. The minus sense RNA may be directly transcribable from the said plant virus DNA or it may be transcribable from a plus sense RNA derived from the said DNA. As such, the minus sense RNA transcribable from a plus sense RNA is referred to, for the purposes of the present invention, as being indirectly transcribable from the said DNA. The orientation or polarity of the cistron or cistrons or parts thereof located on the minus sense RNA molecule can be such that the eliciting element may not be directly coded for after transcription from the plant virus DNA construct. The genetic code of the cistron or cistrons or parts thereof is located on the complementary strand to the minus sense RNA molecule ie the plus sense RNA. The cistron coding for an eliciting element becomes available for translation when the minus sense viral RNA sequence is replicated by an RNA dependent RNA polymerase encoded for by an invading virus to yield a plus sense RNA molecule.

Minus sense RNA herein also includes those RNA molecules which can be described as having ambisense characteristics, such as RNA molecules from tospoviruses and the like. In such cases, the minus sense RNA contains at least a cistron corresponding to a portion of the said plant virus DNA and is capable of giving rise to a plus sense RNA transcribable from the said minus sense RNA which is capable of coding for and giving rise to at least one eliciting element or part thereof in plant cells.

A plus sense viral RNA molecule is one which is capable of directly or indirectly encoding at least one eliciting element or part thereof capable of being expressed in, and having a natural or engineered plant defense eliciting activity in plant cells. A plus sense RNA molecule is also one which is complementary to a viral minus sense RNA and is capable of giving rise directly or indirectly to at least one elicitor element upon translation in plant cells. Thus, a viral sense RNA molecule can be viewed as a complementary RNA molecule to a minus sense RNA molecule.

Plus sense RNA herein also includes those RNA molecules which can be described as having ambisense characteristics. In such cases, the plus sense RNA contains at least a cistron corresponding to a portion of the said plant virus DNA and is capable of directly coding for and giving rise to at least one eliciting element or part thereof in plant cells.

The amount of eliciting element which is expressed in the plant cell must be sufficient to elicit at least a cellular plant defense response against an invading virus resulting in a natural or engineered plant reaction effective in blocking or restricting further viral action. Thus, plus sense RNA molecules whether they be the complement of a minus sense RNA or an ambisense RNA must be capable of giving rise to elicitor elements which are capable of triggering or eliciting a natural or engineered plant defence response, whether that be through direct translation or through interaction with a viral RNA dependent RNA polymerase (eg via a generated subgenomic RNA). There can be one or more eliciting elements ultimately encoded by the plus sense RNA depending on the type of plant defense response/plant defence responses being elicited. The viral plus sense RNA sequence is preferably one wherein at least a viral cistron has been replaced by at least a cistron coding for an eliciting element capable of being expressed in plant cells, and having a natural or engineered plant defense eliciting activity in plant tissue.

The eliciting element can be any element translatable from a plus sense RNA cistron derivable from a plant virus DNA as hereinbefore described, and can be a protein, polypeptide, or peptide or fragments thereof. Examples of preferred eliciting elements include the so-called elicitor proteins and/or cell inhibitory proteins.

An elicitor protein is one which if present in plant tissue, is capable of eliciting, triggering, or inducing a hypersensitive response (HSR), that is a natural plant defense mechanism against invading pathogens such as viruses. Elicitor proteins can be of plant virus origin, such as coat proteins, proteins involved in cell-to-cell movement, helicases, RNA-dependent RNA polymerases and the like. In addition, elicitor proteins can originate from or be derived from other plant pathogens such as bacteria, fungi, nematodes and the like.

A cell inhibitory protein is a protein which if present in plant tissue, has a detrimental effect on the plant cell, leading to inhibition of cell growth eg cell division, and/or cell death. Cell inhibitory agents include but are not restricted to ribonucleases, proteinases, ribosomal inhibitory proteins, cell wall degrading proteins and the like.

The minus and plus sense RNA molecules can be viewed as plant virus RNAs since they are derived from a plant DNA construct as hereinbefore described and comprise the genome or a segment of the genome of a plant virus. In such plant virus RNAs, selected nucleotide fragments can be replaced by others or can be deleted. Replacement and/or deletion of nucleotides or segments comprised of nucleotides should be such so as not to interfere with the capability of the RNA molecule to multiply or replicate in virus-infected plant cells. Also, replacement and/or deletion of nucleotides, codons or segments comprised of nucleotides should be such so as not to interfere with the ability of the RNA dependent RNA polymerase of the invading virus to recognise and act upon an RNA molecule (in plus or minus sense orientation), and thereby initiating the sequence of events as described herein leading to the production of an effective amount of an eliciting element capable of eliciting a natural or engineered plant defense response. Examples of suitable plant virus RNA molecules include, but are not limited to genomic RNA molecules or segments thereof selected from the group comprising potyviruses, potexviruses, tobamoviruses, luteoviruses or genomic RNA or segments thereof of cucumoviruses, bromoviruses, tospoviruses and the like.

The plant virus DNA is under expression control of a promoter capable of functioning in plants and includes a terminator capable of functioning in plants.

A promoter is the nucleotide sequence upstream from the transcriptional initiation site and which contains all the regulatory regions required for transcription. Examples of promoters suitable for use in DNA constructs of the present invention include viral, fungal, bacterial, animal and plant-derived promoters capable of functioning in plant cells. A preferred promoter should express the DNA constitutively, that is in all living tissues of the plant. It will be appreciated that the promoter employed should give rise to the expression of the viral plant DNA at a rate sufficient to produce the amount of RNA capable of encoding for at least an elicitor element capable of eliciting a natural plant defense in a transformed plant on invasion of the plant by a virus. The required amount of RNA to be transcribed may vary with the type of plant. Examples of suitable promoters include the cauliflower mosaic virus 35S (CaMV 35S) and 19S (CaMV 19S) promoters, the nopaline synthase and octopine synthase promoters, the heat shock 80 (hsp80) promoter and the like.

A terminator is contemplated as (A) a DNA sequence downstream of the viral DNA, coding for transcription into an RNA sequence which is capable of autocatalytical, self cleavage, to release the terminator sequences from the recombinant viral RNA sequence, followed by (B) a DNA sequence at the end of a transcriptional unit which signals termination of transcription. These elements are 3'-non-translated sequences containing polyadenylation signals, which act to cause the addition of poly adenylate sequences to the 3' end of primary transcripts. Examples of sequences mentioned under (A) include self-cleaving RNA molecules or ribozymes such as ribonuclease P, Tetrahymena L-19 intervening sequence, hammerhead ribozymes, Hepatitis delta virus RNA, Neurospora mitochondrial VS RNA and the like Symons, R. H. (1992). Ann. Rev. Biochem. 61:641!. Sequences mentioned under (B) may be isolated from funghi, bacteria, animals and/or plants. Examples, particularly suitable for use in the DNA constructs of the invention include the nopaline synthase polyadenylation signal of Agrobacterium tumefaciens, the 35S polyadenylation signal of CaMV and the zein polyadenylation signal from Zea mays.

A DNA or RNA sequence is complementary to another DNA or RNA sequence if it is able to form a hydrogen-bonded complex with it, according to rules of base pairing under appropriate hybridization conditions. For the purposes of the present invention appropriate hybridization conditions may include but are not limited to, for example, an incubation for about 16 hours at 42° C., in a buffer system comprising 5×standard saline citrate (SSC), 0.5% sodium dodecylsulphate (SDS), 5×Denhardt's solution, 50% formamide and 100 μg/ml carrier DNA or RNA (hereinafter the buffer system), followed by washing 3× in buffer comprising 1×SSC and 0.1% SDS at 65° C. for approximately an hour each time. Thus the hybridisation signal obtained for an RNA or DNA molecule, for example an autoradiogram reading, should be sufficiently clear to the man skilled in the art so as to suggest that an RNA or DNA molecule obtained could usefully be employed in the construction of plant virus DNA constructs suitable for use in the invention. Naturally, such an RNA or DNA molecule should be capable of the requisite activity as described herein. Thus replacement and/or deletion of nucleotides, codons or segments comprised of nucleotides should be such so as not to interfere with the ability of a DNA construct of the invention to code for a minus sense RNA molecule as herein described which is capable of being recognised by and of interaction with an RNA dependent RNA polymerase of an invading virus and thereby initiating the sequence of events as described herein leading to the production of an effective amount of an eliciting element capable of eliciting a natural or engineered plant defense response.

Suitable hybridization conditions employed in the present invention can involve incubation in a buffer system for about 16 hours at 49° C. and washing 3× in a buffer comprising 0.1×SSC and 0.1% SDS at 55° C. for about an hour each time. More preferably, hybridization conditions can involve incubation in a buffer system for about 16 hours at 55° C. and washing 3× in a buffer comprising 0.1×SSC and 0.1% SDS at 65° C. for approximately an hour each time. Naturally, any RNA or DNA molecule subjected to such hybridisation conditions should be capable of the requisite activity as described herein.

The invention also provides a vector capable of introducing the DNA construct of the invention into plants and methods of producing such vectors. The term vector employed herein refers to a vehicle by means of which DNA molecules or fragments thereof can be incorporated into a host organism. Suitable vehicles include plasmids, naked DNA introduced using micro-injection, particle guns, and the like Offringa (1992). PhD thesis, State University Leiden, The Netherlands, Ch1:pages 7-28!.

The term plants as used herein is used in a wide sense and refers to differentiated plants as well as undifferentiated plant material such as protoplasts, plant cells, seeds, plantlets and the like which under appropriate conditions can develop into mature plants, the progeny thereof and parts thereof such as cuttings and fruits of such plants.

The invention further provides plants comprising in their genome a DNA construct of the invention, and methods of producing such plants.

The plants according to the invention have reduced susceptibility to diseases caused by the respective viruses and do not have the disadvantages and limitations of plants obtained by classical methods and genetic engineering methods as discussed herein.

The invention is illustrated by the following non-limiting examples and accompanying figures.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1: Schematic representation of the interaction of pathogen and plant encoded proteins leading to induction of an HSR response.

FIG. 2: Schematic representation of CMV resistant tobacco or tomato plants, obtained by expression of a minus-sense CMV RNA 3 molecule in which the MP gene is replaced by a gene coding for an elicitor (ToMV CP or P30) or a cell inhibitory protein (RNase T1).

FIG. 3: Schematic representation of CMV resistant tobacco or tomato plants obtained by expression of a plus-sense CMV RNA 3 molecule in which the CP gene is replaced by a gene coding for an elicitor (ToMV CP or P30) or a cell inhibitory protein (RNase T1).

Sequence ID 1: Chimaeric cucumber mosaic virus RNA 3.

Sequence ID 2: Coat protein of ToMV (corresponding to nucleotides from positions 123-600 of Seq. ID. No.1).

Sequence ID 3: Coat protein of cucumber mosaic virus corresponding to nucleotide positions from 897-1550 of Seq. ID. No 1.

Sequence ID 4: Chimaeric cucumber mosaic virus RNA 3.

Sequence ID 5: RNAse T1 corresponding to positions 123-437 of Seq. ID No. 4.

Sequence ID 6: Chimaeric cucumber mosaic virus RNA 3, coding for P30 of ToMV.

Sequence ID 7: P30 of ToMV corresponding to nucleotide positions 123-914 of Seq. ID No.7.

Sequence ID 8: Chimaeric tomato spotted wilt virus S RNA, coding for the coat protein of ToMV and the non-structural protein, NSs in opposite polarity.

Sequence ID 9: The non-structural protein, NSs (in opposite polarity) corresponding to nucleotide positions 1141-2543 of Seq ID No.8.

EXAMPLES

All CMV, TSWV, and ToMV RNA-derived sequences presented here are depicted as DNA sequences for the sole purpose of uniformity. It will be appreciated that this is done for convenience only.

Cultivars of Nicotiana tabacum and Lycopersicon esculentum, used in plant transformation studies, are grown under standard greenhouse conditions. Axenic explant material is grown on standard MS media Murashige and Skoog (1962). Physiol. Plant 15:473! containing appropriate phytohormones and sucrose concentrations.

E. coli bacteria are grown on rotary shakers at 37° C. in standard LB-medium. Agrobacterium tumefaciens strains are grown at 28° C. in MinA medium supplemented with 0.1% glucose Ausubel et al., (1987). Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Inter-sciences, New York, Chichester, Brisbane, Toronto, and Singapore!.

In all cloning procedures the E. coli strain JM83, (F⁻, Δ(lac-pro), ara, rpsL, φ80, dlacZM15) is used as the preferred recipient for recombinant plasmids.

Binary vectors are conjugated to Agrobacterium tumefaciens strain LBA 4404, a strain containing the Ti-plasmid vir region, Hoekema et al (1983). Nature 303: 179! in standard triparental matings using the E. coli HB101, containing the plasmid pRK2013 as a helper strain. Figurski and Helinski, (1979). Proc. Natl. Acad. Sci. U.S.A. 76: 1648!. Appropriate Agrobacterium tumefaciens recipients are selected on media containing rifampicin (50 μg/ml) and kanamycine (50 μg/ml).

Cloning of fragments in the vectors pUC19 Yanish-Perron et al (1985). Gene 33: 103!, pBluescript (Stratagene), pBIN19 Bevan et al (1984). Nucl. Acids Res. 12: 8711! or derivatives, restriction enzyme analysis of DNA, transformation to E. coli recipient strains, isolation of plasmid DNA on small as well as large scale, nick-translation, in vitro transcription, DNA sequencing, Southern blotting and DNA gel electrophoresis are performed according to standard procedures Maniatis et al (1982).

Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, New York; Ausubel et al supra, (1987)!.

DNA amplification using the polymerase chain reaction (PCR) was performed as recommended by the supplier of the Taq polymerase (Perkin Elmer Cetus). Amplification of RNA by reverse transcription and subsequent standard DNA amplification was performed using the Gene Amp RNA PCR as recommended by the supplier (Perkin Elmer Cetus).

Example 1

Isolation of CMV particles and genetic material therein

A CMV serogroup I is isolated from squash and maintained on squash by mechanical passaging. Virus is purified from systemically infected squash leaves essentially following the procedure according to Francki et al (1979) CMI/AAB Descr. of Plant Viruses 213!. Approximately 100 μg of virus in a volume of 250 μl is extracted with phenol, then with a mixture of phenol and chloroform and finally with chloroform. RNA is precipitated with ethanol and collected by centrifugation. The pellet is dissolved in 20 μl of water.

Example 2

Isolation of ToMV particles and genetic material therein

A ToMV isolate from tomato, is maintained on tobacco via mechanical passaging. Virus is purified from systemically infected tobacco leaves essentially following the method essentailly according to Hollings & Huttinga (1976) CMI/AAB Descr. of Plant Viruses 156!. Approximately 200 μg of virus in a volume of 300 μl is extracted with phenol, then with a mixture of phenol and chloroform and finally with chloroform. The RNA is precipitated with ethanol and collected by centrifugation. The pellet is dissolved in 50 μl of water.

Example 3

Molecular cloning of CMV RNA 3

The sequence of RNA 3 of CMV is isolated using RNA-based PCR on purified CMV RNA (Perkin Elmer Cetus supra). Two primers are designed, ZUP069:

(5' TTTGGATCCA CGTGGTCTCC TTTTGGAG 3'),

which is complementary to the first 16 nucleotides at the 3' end of RNA 3 of CMV (Seq. Id No.1), and ZUP068:

(5' TTTGGATCCG TAATCTTACC ACT 3')

which is identical to the first 14 nucleotides at the 5' end of RNA 3 of CMV (Seq. Id. No.1). Both primers contain BamH1 restriction sites to enable further cloning of the amplified DNA molecules. Purified CMV RNA is subjected to the Gene Amp RNA PCR, and the resulting PCR fragment is isolated from an agarose gel and cloned into Sma1-linearized pUC19, yielding the recombinant plasmid pZU181.

Example 4

Molecular cloning of TSWV S RNA

A cDNA clone containing almost the complete TSWV S RNA-specific sequence was constructed by fusion of cDNA clones 520 and 614 on the unique EcoR1 site yielding pTSWV-S1 De Haan et al (1990). J. Gen. Virol. 71: 1001!. The complete sequence of TSWV S RNA is isolated using RNA-based PCR on purified pTSWV-S1 DNA (Perkin Elmer Cetus supra). Two primers are designed, ZUP250:

5' (TTTGGATCCA GAGCAATCGT GTCAATTTTG TGTTCATACC TTAAC) 3'

which comprises 36 nucleotides identical to the first 36 nucleotides at the 5' end of TSWV S RNA (Seq. Id. No.8), and ZUP251:

5' (TTTGGATCCA GAGCAATTGT GTCAGAATTT TGTTCATAAT CAAACCTCAC TT) 3'

which comprises 43 nucleotides complimentary to the first 43 nucleotides at the 3' end of TSWV S RNA (Seq. Id. No.8). Both primers contain BamHl restriction sites to enable further cloning of the amplified DNA molecules. The resulting PCR fragment is isolated from an agarose gel and cloned into Sma1-linearized pUC19, yielding the recombinant plasmid pTSWV-S2.

Example 5

Molecular cloning of the CP and P30 genes of ToMV

The sequence of the genes corresponding to the coat protein (CP) and P30 of ToMV is isolated using RNA-based PCR. Primer ZUP112 spans either side of the translational start codon of the CP gene of ToMV RNA:

5' GTATTAACCA TGGCTTACTC 3' (comprising 13 nucleotides identical to nucleotides 121-133 of Seq. Id. No.1) and

primer ZUP113 spans either side of the translational stop codon of the CP gene of ToMV RNA:

5' GCACCCATGG ATTTAAGATG 3' (comprising 16 nucleotides complementary to nucleotides 595-610 of Seq. Id. No.1), and

primer ZUP117 spans either side of the translational start codon of the P30 gene of ToMV RNA:

5' TATTTCTCCA TGGCTCTAGT 3' (comprising 13 nucleotides identical to nucleotides 121-133 of Seq. Id No.6), and

primer ZUP118 spans either side of the translational stop codon of the P30 gene of ToMV RNA:

5' GAGTAAGCCA TGGTTAATAC 3' (comprising 13 nucleotides complementary to nucleotides 911-923 of Seq. Id. No.6)

The primers contain Nco1 restriction sites to enable further cloning of the amplified DNA molecules. Purified ToMV RNA is subjected to the Gene Amp RNA PCR. Resulting PCR fragments are isolated from an agarose gel and cloned into Sma1-linearized pUC19, yielding the recombinant plasmids pZU183 (containing the CP gene) and pZU206 (containing the P30 gene).

Example 6

Synthesis of the ribonuclease T1 gene

The sequence of the gene corresponding with ribonuclease T1 is synthesized on a commercial DNA synthesizer (Pharmacia LKB, Gene assembler plus) as primer ZUP110 (comprising nucleotides identical to nucleotides 121-293 of Seq. Id No.4):

    5' TTTCCATGGC ATGCGACTAC ACTTGCGGTT CTAACTGCTA CTCTTCTTCA        GACGTTTCTA CTGCTCAAGC TGCCGGATAT AAACTTCACG AAGACGGTGA        AACTGTTGGA TCTAATTCTT ACCCACACAA ATACAACAAC TACGAAGGTT        TTGATTTCTC TGTGAGCTCT CCCTAC 3'

and primer ZUP111 (comprising nucleotides complementary to nucleotides 278-446 of Seq. Id. No.4):

    5' GGGCCATGGT TATGTACATT CAACGAAGTT GTTACCAGAA GCACCAGTGT        GAGTGATAAC ACCAGCATGT TGGTTGTTTT CGTTGAAGAC GACACGGTCA        GCACCTGGAG AAGGACCAGA GTAAACATCA CCGCTAGAGA GGATAGGCCA        TTCGTAGTAG GGAGAGCTCA C 3'

Both primers contain Nco1 restriction sites to enable further cloning of the amplified DNA molecules. The primers are annealed and subjected to a standard DNA PCR. The amplified DNA fragment is isolated from an agarose gel and cloned into Sma1-linearized pUC19, yielding the recombinant plasmid pZU230.

Example 7

Construction of an expression vector pZU-A

The 35S cauliflower mosaic virus (CaMV) promoter fragment is isolated from the recombinant plasmid pZO27, a derivative of pUC19 carrying as a 444 bp HindIII-PstI fragment the HincII-HphI region of the 35S promoter of CaMV strain Cabb-S Franck et al (1980). Cell 21: 285-294!. The nucleotide sequences of CaMV strains are very similar for the different strains. The 35S promoter fragment is excised from pZO27 as a 472 bp EcoRI-PstI fragment which contains: a part of the polylinker region, 437 bp of the non-transcribed region and the transcription initiation site and 7 bp of the non-translated leader region but not containing any 35S translational initiators. The 35S promoter fragment is ligated using T4 ligase into EcoRI-PstI linearized pZO008. The plasmid pZO008 carries the nopaline synthase (NOS) polyadenylation signal as a 270 bp PstI-HindIII fragment. The resulting recombinant plasmid pZU-A carries the 35S promoter, a unique PstI site and the NOS terminator Gielen et al (1991) Bio/Technology 10:1363!.

Example 8

Construction of a plant transformation vector, which yields a transcript which replicates upon infection with CMV

The 5' end of the minus-sense RNA 3 of CMV is fused directly to the transcription initiation site of the CaMV 35S promoter using two primers ZUP148:

5' CCACGTCTTC AAAGCAAG 3' (complementary to nucleotides of the CaMV 35S promoter), and primer ZUP146:

5' CTTCGCACCT TCGTGGGGGC TCCAAAAGGA GACCACCTCT CCAAATGAAA 3' (comprising nucleotides complementary to nucleotides 1860-1827 of Seq. Id. No.1)

with pZU-A as a template in a standard DNA PCR reaction. The amplified DNA fragment is digested with EcoRV and cloned in EcoRV linearized pZU-A. The resulting plasmid is digested with BstX1 and Pst1 and purified on an agarose gel. pZU181 is digested with Pst1 and BstX1, the 2.1 kb insert DNA is purified on an agarose gel and subsequently cloned into the gel-purified pZU-A derivative, yielding pCMV3AS-1.

The movement protein (MP) coding domain of pCMV3AS-1 is replaced by a unique Nco1 cloning site and the axehead structure of the Hepatitis delta viral RNA is cloned downstream of the 3' end of the minus-sense RNA 3 of CMV, by PCR amplification of two DNA fragments using pCMV3AS-1 as a template. The first DNA fragment is amplified using primers ZUP050:

5' AGCTGCTAAC GTCTTATTAA G 3' (comprising nucleotides complementary to nucleotides 1020-1039 of Seq. Id. No.1)

and ZUP329:

5' GTCTTTAGCA CCATGGTG 3' (comprising nucleotides identical to nucleotides 604-612 of Seq Id. No.1)

The DNA fragment is digested with Nru1 and Nco1 and a 411 bp long DNA fragment (position 607-1016 Seq. Id. No.1) is isolated from an agarose gel. The second DNA fragment is amplified using primers ZUP327:

5' GGAGAGCCAT GGCTCGGG 3' (comprising nucleotides complementary to nucleotides 115-126 of Seq. Id. No.1)

and ZUP350, a primer synthesised with nucleotides comprising nucleotides complementary to antigenomic hepatitis delta virus RNA as described by Perrotta A. T. & Been M. D. (1991) Nature Vol 350(4) pp434-436 ligated to nucleotides identical to nucleotides 1-14 (3' end of the primer) of Seq. Id. No. 1:

    5'TTTCTGCAGA TCTTAGCCAT CCGAGTGGA CGTGCGTCCT CCTTCGGATG       CCCAGGTCGG  ACCGCGAGGA  GGTGGAGATG  CCATGCCGAC  CCGTAATCTT     ACCACT)3'.

The DNA fragment is digested with Pst1 and Nco1 and a 208 bp. long DNA fragment is isolated from an agarose gel. Both isolated DNA fragments are cloned in pCMV3AS-1, linearized with Pst1 and Nru1, to yield pCMV3AS-2. Genes coding for elicitors (example 5) or cell inhibitory proteins (example 6) can be cloned as Nco1 DNA fragments into the unique Nco1 site of pCMV3AS-2. The resulting pCMV3AS-2 derived plasmids are digested with HindIII and the DNA fragments containing the chimaeric genes are isolated from an agarose gel and ligated into HindIII linearized pBIN19, resulting in binary plant transformation vectors pBINCMV3-CP, pBINCMV3-P30 and pBINCMV3-T1 respectively.

Example 9

Construction of a plant transformation vector, which yields a transcript which replicates upon infection with TSWV

The 5' end of the minus-sense TSWV S RNA is fused directly to the transcription initiation site of the CaMV 35S promoter using two primers ZUP148 (Example 8), and primer ZUP255:

5' ACACAATTGC TCTCCTCTCC AAATGAAA 3' (comprising nucleotides identical to nucleotides 2608-2621 of Seq. Id. No.8)

with pZU-A as a template in a standard DNA PCR reaction. The amplified DNA fragment is digested with EcoRV and cloned in EcoR5 linearized pZU-A. The resulting plasmid is digested with Mun1 and Pst1 and purified on an agarose gel. pTSWV-S2 is digested with Pst1 and Mun1, the 2.9 kb insert DNA is purified on an agarose gel and subsequently cloned into the gel-purified pZU-A derivative, yielding pTSWVSAS-1.

The N coding domain of pTSWVSAS-1 is replaced by a unique Nco1 cloning site and the axehead structure of the Hepatitis delta viral RNA is cloned downstream of the 3' end of the minus-sense TSWV S RNA, by PCR amplification of two DNA fragments using pTSWVSAS-1 as a template. The first DNA fragment is amplified using primers ZUP252:

5' GACCCGAAAG GGACCAATTT C 3' (comprising nucleotides complimentary to nucleotides 911-930 of Seq Id. No.8)

and ZUP253:

5' TTTCCATGGC TGTAAGTTAA ATT 3' (comprising nucleotides identical to nucleotides 636-655 of Seq Id. No.8)

The DNA fragment is digested with Ba11 and Nco1 and a 269 bp long DNA fragment (position 636-911 Sequence Id No.8) is isolated from an agarose gel. The second DNA fragment is amplified using primers ZUP254:

5' TTTCCATGGT GATCGTAAAA G 3' (comprising nucleotides complementary to nucleotides 140-157 of Seq. Id No.8)

and ZUP255 a primer synthesised with nucleotides comprising nucleotides complementary to antigenomic hepatitis delta virus RNA as described by Perrotta A. T. & Been M. D. (1991) Nature Vol 350(4) pp434-436, ligated to nucleotides identical to nucleotides 1-14 (3' end of the primer) of Seq. Id. No. 8:

    5' TTTCTGCAGA TCTTAGCCAT CCGAGTGGAC GTGCGTCCTC CTTCGGATGC        CCAGGTCGGA CCGCGAGGAG GTGGAGATGC CATGCCGACC CAGAGCAATC        GTGTC 3'

The DNA fragment is digested with Pst1 and Nco1 and a 245 bp. long DNA fragment is isolated from an agarose gel. Both isolated DNA fragments are cloned in pTSWVSAS-1, linearized with Pst1 and Ba11, to yield pTSWVSAS-2. Genes coding for elicitors (example 5) or cell inhibitory proteins (example 6) are cloned as Nco1 DNA fragments into the unique Nco1 site of pTSWVSAS-2. The resulting pTSWVSAS-2 derived plasmids are digested with Xba1 and the DNA fragments containing the chimaeric genes are isolated from an agarose gel and ligated into Xba1 linearized pBIN19, resulting in binary plant transformation vectors pBINTSWVS-CP (Seq Id No.8), pBINTSWVS-P30 and pBINTSWVS-T1 respectively.

Example 10

Selection of suitable host plants

1) Tobacco, Nicotiana tabacum var. Samsun EN. A tobacco cultivar harboring the N' gene of N. sylvestris showing an HS response upon infection with ToMV. The CP of ToMV elicits a strong HSR defense reaction in this host. 2) Tomato, Lycopersicon esculentum var. ATV847, parental line for commercial hybrids Yaiza and Gemma. A tomato line harboring the Tm-2² resistance gene to ToMV. It has been demonstrated that the P30 of ToMV elicits a HS response in this resistag30 nt genotype Fraser (1986) CRC Crit. Rev. Plant Sci.3: 257; Keen (1990). Ann. Rev. Genet. 24: 447!.

Example 11

Transformation of binary vectors to tobacco and tomato plant material

Methods to transfer binary vectors to plant material are well established and known to a person skilled in the art. Variations in procedures exist due to for instance differences in used Agrobacterium strains, different sources of explant material, differences in regeneration systems depending on as well the cultivar as the plant species used.

The binary plant transformation vectors as described above are used in plant transformation experiments according to the following procedures. Binary vector constructs are transferred by tri-parental mating to an acceptor Agrobacterium tumefaciens strain, followed by southern analysis of the ex-conjugants for verification of proper transfer of the construct to the acceptor strain, inoculation and cocultivation of axenic explant material with the Agrobacterium tumefaciens strain of choice, selective killing of the Agrobacterium tumefaciens strain used with appropriate antibiotics, selection of transformed cells by growing on selective media containing kanamycine, transfer of tissue to shoot-inducing media, transfer of selected shoots to root inducing media, transfer of plantlets to soil, assaying for intactness of the construct by southern analyses of isolated total DNA from the transgenic plant, assaying for proper function of the inserted chimaeric gene by northern analysis and/or enzyme assays and western blot analysis of proteins Ausubel et al supra, (1987)!.

Example 12

Expression of chimaeric sequences in tobacco and tomato plant cells

RNA is extracted from leaves of regenerated plants using the following protocol. Grind 200 mg leaf material to a fine powder in liquid nitrogen. Add 800 μl RNA extraction buffer (100 mM Tris-HCl (pH 8,0), 500 mM NaCl, 2 mM EDTA, 200 mM 62-Mercaptoethanol, 0,4% SDS) and extract the homogenate with phenol, collect the nucleic acids by alcohol precipitation. Re suspend the nucleic acids in 0,5 ml 10 mM Tris-HCl (pH 8,0), 1 mM EDTA, add LiCl to a final concentration of 2M, leave on ice for maximally 4 hours and collect the RNA by centrifugation. Re suspend in 400 μl 10 mM Tris-HCl (pH 8,0), 1 mM EDTA and precipitate with alcohol, finally re-suspend in 50 μl 10 mM Tris-HCl (pH 8,0), 1 mM EDTA. RNAs are separated on glyoxal/agarose gels and blotted to Genescreen as described by van Grinsven et al (1986). Theor. Appl. Gen. 73:94-101!. Recombinant viral RNA sequences are detected using DNA or RNA probes labeled with ³² P!, ³⁵ S! or by using non-radioactive labeling techniques. Based on northern analysis, it is determined to what extent the regenerated plants express the chimaeric recombinant viral genes.

Plants transformed with recombinant viral DNA sequences are also subjected to western blot analysis after inoculation with the respective virus. Proteins are extracted from leaves of transformed plants by grinding in sample buffer according to Laemmli (1970). Nature 244: 29!. A 50 μg portion of protein is subjected to electrophoresis in a 12,5% SDS-polyacrylamide gel essentially as described by Laemmli supra, (1970). Separated proteins are transferred to nitrocellulose electrophoretically as described by Towbin et al (1979). Proc. Natl. Acad. Sci. U.S.A. 76: 4350!. Transferred proteins are reacted with antiserum raised against purified ToMV particles or against purified P30 protein, according to Towbin et al supra, (1979). Based on the results of the western analysis, it is determined that transformed plants do express elicitor proteins after inoculation with the respective virus.

Example 13

Resistance of tobacco and tomato plants against CMV or TSWV infection

Transformed plants are grown in the greenhouse under standard quarantine conditions in order to prevent any infections by pathogens. The transformants are self-pollinated and the seeds harvested. Progeny plants are analyzed for segregation of the inserted gene and subsequently infected with CMV or TSWV by mechanical inoculation. Tissue from plants systemically infected with CMV or TSWV is ground in 5 volumes of ice-cold inoculation buffer (10 mM phosphate buffer) and rubbed in the presence of carborundum powder on the first two fully extended leafs of approximately 5 weeks old seedlings. Inoculated plants are monitored for symptom development during 3 weeks after inoculation.

Plants containing CMV Related DNA Sequences or TSWV related DNA sequences show reduced susceptibility to CMV or TSWV infection compared with untransformed control plants which show severe systemic CMV or TSWV symptoms within 7 days after inoculation.

    __________________________________________________________________________     #             SEQUENCE LISTING     - (1) GENERAL INFORMATION:     -    (iii) NUMBER OF SEQUENCES: 30     - (2) INFORMATION FOR SEQ ID NO:1:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 1860 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (vi) ORIGINAL SOURCE:     #cucumber mosaic virus RNA 3aeric     -     (ix) FEATURE:               (A) NAME/KEY: CDS               (B) LOCATION: 123..599     -     (ix) FEATURE:               (A) NAME/KEY: CDS               (B) LOCATION: 897..1550     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:     - GTAATCTTAC CACTCGTGTG TGTGCGTGTG TGTGTGTCGA GTCGTGTTGT CC - #GCACATTT       60     - GAGTCGTGCT GTCCGCACAT ATATTTTACC TTTTGTGTAC AGTGTGTTAG AT - #TTCCCGAG      120     - CC ATG GCT TAC TCA ATC ACT TCT CCA TCG CAA - # TTT GTG TTT TTG TCA      167     #Gln Phe Val Phe Leu Serhr Ser Pro Ser     #  15     - TCT GTA TGG GCT GAC CCT ATA GAA TTG TTA AA - #C GTT TGT ACA AAT TCG      215     Ser Val Trp Ala Asp Pro Ile Glu Leu Leu As - #n Val Cys Thr Asn Ser     #                 30     - TTA GGT AAC CAG TTT CAA ACA CAG CAA GCA AG - #A ACT ACT GTT CAA CAG      263     Leu Gly Asn Gln Phe Gln Thr Gln Gln Ala Ar - #g Thr Thr Val Gln Gln     #             45     - CAG TTC AGC GAG GTG TGG AAA CCT TTC CCT CA - #G AGC ACC GTC AGA TTT      311     Gln Phe Ser Glu Val Trp Lys Pro Phe Pro Gl - #n Ser Thr Val Arg Phe     #         60     - CCT GGC GAT GTT TAT AAG GTG TAC AGG TAC AA - #T GCA GTT TTA GAT CCT      359     Pro Gly Asp Val Tyr Lys Val Tyr Arg Tyr As - #n Ala Val Leu Asp Pro     #     75     - CTA ATT ACT GCG TTG CTG GGG TCT TTC GAT AC - #T AGG AAT AGA ATA ATC      407     Leu Ile Thr Ala Leu Leu Gly Ser Phe Asp Th - #r Arg Asn Arg Ile Ile     # 95     - GAA GTA GAA AAC CAG CAG AAT CCG ACA ACA GC - #T GAA ACG TTA GAT GCT      455     Glu Val Glu Asn Gln Gln Asn Pro Thr Thr Al - #a Glu Thr Leu Asp Ala     #               110     - ACC CGC AGG GTA GAC GAC GCT ACG GTT GCA AT - #T CGG TCT GCT ATA AAT      503     Thr Arg Arg Val Asp Asp Ala Thr Val Ala Il - #e Arg Ser Ala Ile Asn     #           125     - AAT TTA GTT AAT GAA CTA GTA AGA GGT ACT GG - #A CTG TAC AAT CAA AAT      551     Asn Leu Val Asn Glu Leu Val Arg Gly Thr Gl - #y Leu Tyr Asn Gln Asn     #       140     - ACT TTT GAA AGT ATG TCT GGG TTG GTC TGG AC - #C TCT GCA CCT GCA TCT      599     Thr Phe Glu Ser Met Ser Gly Leu Val Trp Th - #r Ser Ala Pro Ala Ser     #   155     - TAAATCCATG GTGTATTAGT ATATAAGTAT TGTGAGTCTG TACATAATAC TA - #TATCTATA      659     - GTGTCCTGTG TGAGTTGATA CAGTAGACAT CTGTGACGCG ATGCCGTGTT GA - #GAAGGGAA      719     - CACATCTGGT TTTAGTAAGC CTACATCACA GTTTTGAGGT TCAATTCCTC AT - #ACTCCCTG      779     - TTGAGTCCCT TACTTTCTCA TGGATGCTTC TCCGCGAGAT TGCGTTATTG TC - #TACTGACT      839     - ATATAGAGAG TGTGTGTGCT GTGTTTTCTC TTTTGTGTCG TAGAATTGAG TC - #GAGTC      896     - ATG GAC AAA TCT GAA TCA ACC AGT GCT GGT CG - #T AAC CGT CGA CGT CGT      944     Met Asp Lys Ser Glu Ser Thr Ser Ala Gly Ar - #g Asn Arg Arg Arg Arg     #                 15     - CCG CGT CGT GGT TCC CGC TCC GCC CCC TCC TC - #C GCG GAT GCT AAC TTT      992     Pro Arg Arg Gly Ser Arg Ser Ala Pro Ser Se - #r Ala Asp Ala Asn Phe     #             30     - AGA GTC TTG TCG CAG CAG CTT TCG CGA CTT AA - #T AAG ACG TTA GCA GCT     1040     Arg Val Leu Ser Gln Gln Leu Ser Arg Leu As - #n Lys Thr Leu Ala Ala     #         45     - GGT CGT CCA ACT ATT AAC CAC CCA ACC TTT GT - #A GGG AGT GAA CGC TGT     1088     Gly Arg Pro Thr Ile Asn His Pro Thr Phe Va - #l Gly Ser Glu Arg Cys     #     60     - AAA CCT GGG TAC ACG TTC ACA TCT ATT ACC CT - #A AAG CCA CCA AAA ATA     1136     Lys Pro Gly Tyr Thr Phe Thr Ser Ile Thr Le - #u Lys Pro Pro Lys Ile     # 80     - GAC CGT GGG TCT TAT TAC GGT AAA AGG TTG TT - #A TTA CCT GAT TCA GTC     1184     Asp Arg Gly Ser Tyr Tyr Gly Lys Arg Leu Le - #u Leu Pro Asp Ser Val     #                 95     - ACG GAA TAT GAT AAG AAA CTT GTT TCG CGC AT - #T CAA ATT CGA GTT AAT     1232     Thr Glu Tyr Asp Lys Lys Leu Val Ser Arg Il - #e Gln Ile Arg Val Asn     #           110     - CCT TTG CCG AAA TTC GAT TCT ACC GTG TGG GT - #G ACA GTC CGT AAA GTT     1280     Pro Leu Pro Lys Phe Asp Ser Thr Val Trp Va - #l Thr Val Arg Lys Val     #       125     - CCT GCC TCC TCG GAC TTA TCC GTT GCC GCC AT - #C TCT GCT ATG TTT GCG     1328     Pro Ala Ser Ser Asp Leu Ser Val Ala Ala Il - #e Ser Ala Met Phe Ala     #   140     - GAC GCC GCA TTT GGA GTC CAA GCT AAC AAC AA - #A TTG TTG TAT GAT CTT     1376     Asp Ala Ala Phe Gly Val Gln Ala Asn Asn Ly - #s Leu Leu Tyr Asp Leu     145                 1 - #50                 1 - #55                 1 -     #60     - TCG GCG GGA GCC TCA CCG GTA CTG GTT TAT CA - #G TAC ATG CGC GCT GAT     1424     Ser Ala Gly Ala Ser Pro Val Leu Val Tyr Gl - #n Tyr Met Arg Ala Asp     #               175     - ATA GGT GAC ATG AGA AAG TAC GCC GTC CTC GT - #G TAT TCA AAA GAC GAT     1472     Ile Gly Asp Met Arg Lys Tyr Ala Val Leu Va - #l Tyr Ser Lys Asp Asp     #           190     - GCG CTC GAG ACG GAC GAG CTA GTA CTT CAT GT - #T GAC ATC GAG CAC CAA     1520     Ala Leu Glu Thr Asp Glu Leu Val Leu His Va - #l Asp Ile Glu His Gln     #       205     - CGC ATT CCC ACA TCT AGA GTA CTC CCA GTC TG - #ATTCCGTG TTCCCAGAAC     1570     Arg Ile Pro Thr Ser Arg Val Leu Pro Val     #   215     - CCTCCCTCCG ATTTCTGTGG CGGGAGCTGA GTTGGCAGTT CTGCTATAAA CT - #GTCTGAAG     1630     - TCACTAAACG TTTTACGGTG AACGGGTTGT CCATCCAGCT TACGGCTAAA AT - #GGTCAGTC     1690     - GTGGAGAAAT CCACGCCAGC AGATTTACAA ATCTCTGAGG CGCCTTTGAA AC - #CATCTCCT     1750     - AGGTTTTTTC GGAAGGACTT CGGTCCGTGT ACCTCTAGCA CAACGTGCTA GT - #CTTAGGGT     1810     #            1860TCTTCG CACCTTCGTG GGGGCTCCAA AAGGAGACCA     - (2) INFORMATION FOR SEQ ID NO:2:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 159 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:     - Met Ala Tyr Ser Ile Thr Ser Pro Ser Gln Ph - #e Val Phe Leu Ser Ser     #                 15     - Val Trp Ala Asp Pro Ile Glu Leu Leu Asn Va - #l Cys Thr Asn Ser Leu     #             30     - Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Th - #r Thr Val Gln Gln Gln     #         45     - Phe Ser Glu Val Trp Lys Pro Phe Pro Gln Se - #r Thr Val Arg Phe Pro     #     60     - Gly Asp Val Tyr Lys Val Tyr Arg Tyr Asn Al - #a Val Leu Asp Pro Leu     # 80     - Ile Thr Ala Leu Leu Gly Ser Phe Asp Thr Ar - #g Asn Arg Ile Ile Glu     #                 95     - Val Glu Asn Gln Gln Asn Pro Thr Thr Ala Gl - #u Thr Leu Asp Ala Thr     #           110     - Arg Arg Val Asp Asp Ala Thr Val Ala Ile Ar - #g Ser Ala Ile Asn Asn     #       125     - Leu Val Asn Glu Leu Val Arg Gly Thr Gly Le - #u Tyr Asn Gln Asn Thr     #   140     - Phe Glu Ser Met Ser Gly Leu Val Trp Thr Se - #r Ala Pro Ala Ser     145                 1 - #50                 1 - #55     - (2) INFORMATION FOR SEQ ID NO:3:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 218 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:     - Met Asp Lys Ser Glu Ser Thr Ser Ala Gly Ar - #g Asn Arg Arg Arg Arg     #                 15     - Pro Arg Arg Gly Ser Arg Ser Ala Pro Ser Se - #r Ala Asp Ala Asn Phe     #             30     - Arg Val Leu Ser Gln Gln Leu Ser Arg Leu As - #n Lys Thr Leu Ala Ala     #         45     - Gly Arg Pro Thr Ile Asn His Pro Thr Phe Va - #l Gly Ser Glu Arg Cys     #     60     - Lys Pro Gly Tyr Thr Phe Thr Ser Ile Thr Le - #u Lys Pro Pro Lys Ile     # 80     - Asp Arg Gly Ser Tyr Tyr Gly Lys Arg Leu Le - #u Leu Pro Asp Ser Val     #                 95     - Thr Glu Tyr Asp Lys Lys Leu Val Ser Arg Il - #e Gln Ile Arg Val Asn     #           110     - Pro Leu Pro Lys Phe Asp Ser Thr Val Trp Va - #l Thr Val Arg Lys Val     #       125     - Pro Ala Ser Ser Asp Leu Ser Val Ala Ala Il - #e Ser Ala Met Phe Ala     #   140     - Asp Ala Ala Phe Gly Val Gln Ala Asn Asn Ly - #s Leu Leu Tyr Asp Leu     145                 1 - #50                 1 - #55                 1 -     #60     - Ser Ala Gly Ala Ser Pro Val Leu Val Tyr Gl - #n Tyr Met Arg Ala Asp     #               175     - Ile Gly Asp Met Arg Lys Tyr Ala Val Leu Va - #l Tyr Ser Lys Asp Asp     #           190     - Ala Leu Glu Thr Asp Glu Leu Val Leu His Va - #l Asp Ile Glu His Gln     #       205     - Arg Ile Pro Thr Ser Arg Val Leu Pro Val     #   215     - (2) INFORMATION FOR SEQ ID NO:4:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 1696 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (vi) ORIGINAL SOURCE:     #cucumber mosaic virus RNA 3aeric     -     (ix) FEATURE:               (A) NAME/KEY: CDS               (B) LOCATION: 123..437     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:     - GTAATCTTAC CACTCGTGTG TGTGCGTGTG TGTGTGTCGA GTCGTGTTGT CC - #GCACATTT       60     - GAGTCGTGCT GTCCGCACAT ATATTTTACC TTTTGTGTAC AGTGTGTTAG AT - #TTCCCGAG      120     - CC ATG GCA TGC GAC TAC ACT TGC GGT TCT AAC - # TGC TAC TCT TCT TCA      167     #Asn Cys Tyr Ser Ser Serhr Cys Gly Ser     #  15     - GAC GTT TCT ACT GCT CAA GCT GCC GGA TAT AA - #A CTT CAC GAA GAC GGT      215     Asp Val Ser Thr Ala Gln Ala Ala Gly Tyr Ly - #s Leu His Glu Asp Gly     #                 30     - GAA ACT GTT GGA TCT AAT TCT TAC CCA CAC AA - #A TAC AAC AAC TAC GAA      263     Glu Thr Val Gly Ser Asn Ser Tyr Pro His Ly - #s Tyr Asn Asn Tyr Glu     #             45     - GGT TTT GAT TTC TCT GTG AGC TCT CCC TAC TA - #C GAA TGG CCT ATC CTC      311     Gly Phe Asp Phe Ser Val Ser Ser Pro Tyr Ty - #r Glu Trp Pro Ile Leu     #         60     - TCT AGC GGT GAT GTT TAC TCT GGT GGT TCT CC - #A GGT GCT GAC CGT GTC      359     Ser Ser Gly Asp Val Tyr Ser Gly Gly Ser Pr - #o Gly Ala Asp Arg Val     #     75     - GTC TTC AAC GAA AAC AAC CAA CTA GCT GGT GT - #T ATC ACT CAC ACT GGT      407     Val Phe Asn Glu Asn Asn Gln Leu Ala Gly Va - #l Ile Thr His Thr Gly     # 95     - GCT TCT GGT AAC AAC TTC GTT GAA TGT ACA TA - #ACCATGGT GTATTAGTAT      457     Ala Ser Gly Asn Asn Phe Val Glu Cys Thr     #               105     - ATAAGTATTG TGAGTCTGTA CATAATACTA TATCTATAGT GTCCTGTGTG AG - #TTGATACA      517     - GTAGACATCT GTGACGCGAT GCCGTGTTGA GAAGGGAACA CATCTGGTTT TA - #GTAAGCCT      577     - ACATCACAGT TTTGAGGTTC AATTCCTCAT ACTCCCTGTT GAGTCCCTTA CT - #TTCTCATG      637     - GATGCTTCTC CGCGAGATTG CGTTATTGTC TACTGACTAT ATAGAGAGTG TG - #TGTGCTGT      697     - GTTTTCTCTT TTGTGTCGTA GAATTGAGTC GAGTCATGGA CAAATCTGAA TC - #AACCAGTG      757     - CTGGTCGTAA CCGTCGACGT CGTCCGCGTC GTGGTTCCCG CTCCGCCCCC TC - #CTCCGCGG      817     - ATGCTAACTT TAGAGTCTTG TCGCAGCAGC TTTCGCGACT TAATAAGACG TT - #AGCAGCTG      877     - GTCGTCCAAC TATTAACCAC CCAACCTTTG TAGGGAGTGA ACGCTGTAAA CC - #TGGGTACA      937     - CGTTCACATC TATTACCCTA AAGCCACCAA AAATAGACCG TGGGTCTTAT TA - #CGGTAAAA      997     - GGTTGTTATT ACCTGATTCA GTCACGGAAT ATGATAAGAA ACTTGTTTCG CG - #CATTCAAA     1057     - TTCGAGTTAA TCCTTTGCCG AAATTCGATT CTACCGTGTG GGTGACAGTC CG - #TAAAGTTC     1117     - CTGCCTCCTC GGACTTATCC GTTGCCGCCA TCTCTGCTAT GTTTGCGGAC GG - #AGCCTCAC     1177     - CGGTACTGGT TTATCAGTAC GCCGCATTTG GAGTCCAAGC TAACAACAAA TT - #GTTGTATG     1237     - ATCTTTCGGC GATGCGCGCT GATATAGGTG ACATGAGAAA GTACGCCGTC CT - #CGTGTATT     1297     - CAAAAGACGA TGCGCTCGAG ACGGACGAGC TAGTACTTCA TGTTGACATC GA - #GCACCAAC     1357     - GCATTCCCAC ATCTAGAGTA CTCCCAGTCT GATTCCGTGT TCCCAGAACC CT - #CCCTCCGA     1417     - TTTCTGTGGC GGGAGCTGAG TTGGCAGTTC TGCTATAAAC TGTCTGAAGT CA - #CTAAACGT     1477     - TTTACGGTGA ACGGGTTGTC CATCCAGCTT ACGGCTAAAA TGGTCAGTCG TG - #GAGAAATC     1537     - CACGCCAGCA GATTTACAAA TCTCTGAGGC GCCTTTGAAA CCATCTCCTA GG - #TTTTTTCG     1597     - GAAGGACTTC GGTCCGTGTA CCTCTAGCAC AACGTGCTAG TCTTAGGGTA CG - #GGTGCCCC     1657     #  1696            GTGG GGGCTCCAAA AGGAGACCA     - (2) INFORMATION FOR SEQ ID NO:5:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 105 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:     - Met Ala Cys Asp Tyr Thr Cys Gly Ser Asn Cy - #s Tyr Ser Ser Ser Asp     #                 15     - Val Ser Thr Ala Gln Ala Ala Gly Tyr Lys Le - #u His Glu Asp Gly Glu     #             30     - Thr Val Gly Ser Asn Ser Tyr Pro His Lys Ty - #r Asn Asn Tyr Glu Gly     #         45     - Phe Asp Phe Ser Val Ser Ser Pro Tyr Tyr Gl - #u Trp Pro Ile Leu Ser     #     60     - Ser Gly Asp Val Tyr Ser Gly Gly Ser Pro Gl - #y Ala Asp Arg Val Val     # 80     - Phe Asn Glu Asn Asn Gln Leu Ala Gly Val Il - #e Thr His Thr Gly Ala     #                 95     - Ser Gly Asn Asn Phe Val Glu Cys Thr     #           105     - (2) INFORMATION FOR SEQ ID NO:6:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 2173 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (vi) ORIGINAL SOURCE:     #cucumber mosaic virus RNA 3aeric     -     (ix) FEATURE:               (A) NAME/KEY: CDS               (B) LOCATION: 123..914     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:     - GTAATCTTAC CACTCGTGTG TGTGCGTGTG TGTGTGTCGA GTCGTGTTGT CC - #GCACATTT       60     - GAGTCGTGCT GTCCGCACAT ATATTTTACC TTTTGTGTAC AGTGTGTTAG AT - #TTCCCGAG      120     - CC ATG GCT CTA GTT GTT AAA GGT AAG GTA AAT - # ATT AAT GAG TTT ATC      167     #Asn Ile Asn Glu Phe Ileys Gly Lys Val     #  15     - GAT CTG TCA AAG TCT GAG AAA CTT CTC CCG TC - #G ATG TTC ACG CCT GTA      215     Asp Leu Ser Lys Ser Glu Lys Leu Leu Pro Se - #r Met Phe Thr Pro Val     #                 30     - AAG AGT GTT ATG GTT TCA AAG GTT GAT AAG AT - #T ATG GTC CAT GAA AAT      263     Lys Ser Val Met Val Ser Lys Val Asp Lys Il - #e Met Val His Glu Asn     #             45     - GAA TCA TTG TCT GAA GTA AAT CTC TTA AAA GG - #T GTA AAA CTT ATA GAA      311     Glu Ser Leu Ser Glu Val Asn Leu Leu Lys Gl - #y Val Lys Leu Ile Glu     #         60     - GGT GGG TAT GTT TGC TTA GTT GGT CTT GTT GT - #G TCC GGT GAG TGG AAT      359     Gly Gly Tyr Val Cys Leu Val Gly Leu Val Va - #l Ser Gly Glu Trp Asn     #     75     - TTC CCA GAT AAT CGC CGT GGT GGT GTG AGT GT - #C TGC ATG GTT GAC AAG      407     Phe Pro Asp Asn Arg Arg Gly Gly Val Ser Va - #l Cys Met Val Asp Lys     # 95     - AGA ATG GAA AGA GCG GAC GAA GCC ACA CTG GG - #G TCA TAT TAC ACT GCT      455     Arg Met Glu Arg Ala Asp Glu Ala Thr Leu Gl - #y Ser Tyr Tyr Thr Ala     #               110     - GCT GCT AAA AAG CGG TTT CAG TTT AAA GTG GT - #C CCA AAT TAC GGT ATT      503     Ala Ala Lys Lys Arg Phe Gln Phe Lys Val Va - #l Pro Asn Tyr Gly Ile     #           125     - ACA ACA AAG GAT GCA GAA AAG AAC ATA TGG CA - #G GTC TTA GTA AAT ATT      551     Thr Thr Lys Asp Ala Glu Lys Asn Ile Trp Gl - #n Val Leu Val Asn Ile     #       140     - AAA AAT GTA AAA ATG AGT GCG GGC TAC TGC CC - #T TTG TCA TTA GAA TTT      599     Lys Asn Val Lys Met Ser Ala Gly Tyr Cys Pr - #o Leu Ser Leu Glu Phe     #   155     - GTG TCT GTG TGT ATT GTT TAT AAA AAT AAT AT - #A AAA TTG GGT TTG AGG      647     Val Ser Val Cys Ile Val Tyr Lys Asn Asn Il - #e Lys Leu Gly Leu Arg     160                 1 - #65                 1 - #70                 1 -     #75     - GAG AAA GTA ACG AGT GTG AAC GAT GGA GGA CC - #C ATG GAA CTT TCG GAA      695     Glu Lys Val Thr Ser Val Asn Asp Gly Gly Pr - #o Met Glu Leu Ser Glu     #               190     - GAA GTT GTT GAT GAG TTC ATG GAG AAT GTT CC - #A ATG TCG GTT AGA CTC      743     Glu Val Val Asp Glu Phe Met Glu Asn Val Pr - #o Met Ser Val Arg Leu     #           205     - GCA AAG TTT CGA ACC AAA TCC TCA AAA AGA GG - #T CCG AAA AAT AAT AAT      791     Ala Lys Phe Arg Thr Lys Ser Ser Lys Arg Gl - #y Pro Lys Asn Asn Asn     #       220     - AAT TTA GGT AAG GGG CGT TCA GGC GGA AGG CC - #T AAA CCA AAA AGT TTT      839     Asn Leu Gly Lys Gly Arg Ser Gly Gly Arg Pr - #o Lys Pro Lys Ser Phe     #   235     - GAT GAA GTT GAA AAA GAG TTT GAT AAT TTG AT - #T GAA GAT GAA GCC GAG      887     Asp Glu Val Glu Lys Glu Phe Asp Asn Leu Il - #e Glu Asp Glu Ala Glu     240                 2 - #45                 2 - #50                 2 -     #55     - ACG TCG GTC GCG GAT TCT GAT TCG TAT TAACCATGG - #T GTATTAGTAT      934     Thr Ser Val Ala Asp Ser Asp Ser Tyr                     260     - ATAAGTATTG TGAGTCTGTA CATAATACTA TATCTATAGT GTCCTGTGTG AG - #TTGATACA      994     - GTAGACATCT GTGACGCGAT GCCGTGTTGA GAAGGGAACA CATCTGGTTT TA - #GTAAGCCT     1054     - ACATCACAGT TTTGAGGTTC AATTCCTCAT ACTCCCTGTT GAGTCCCTTA CT - #TTCTCATG     1114     - GATGCTTCTC CGCGAGATTG CGTTATTGTC TACTGACTAT ATAGAGAGTG TG - #TGTGCTGT     1174     - GTTTTCTCTT TTGTGTCGTA GAATTGAGTC GAGTCATGGA CAAATCTGAA TC - #AACCAGTG     1234     - CTGGTCGTAA CCGTCGACGT CGTCCGCGTC GTGGTTCCCG CTCCGCCCCC TC - #CTCCGCGG     1294     - ATGCTAACTT TAGAGTCTTG TCGCAGCAGC TTTCGCGACT TAATAAGACG TT - #AGCAGCTG     1354     - GTCGTCCAAC TATTAACCAC CCAACCTTTG TAGGGAGTGA ACGCTGTAAA CC - #TGGGTACA     1414     - CGTTCACATC TATTACCCTA AAGCCACCAA AAATAGACCG TGGGTCTTAT TA - #CGGTAAAA     1474     - GGTTGTTATT ACCTGATTCA GTCACGGAAT ATGATAAGAA ACTTGTTTCG CG - #CATTCAAA     1534     - TTCGAGTTAA TCCTTTGCCG AAATTCGATT CTACCGTGTG GGTGACAGTC CG - #TAAAGTTC     1594     - CTGCCTCCTC GGACTTATCC GTTGCCGCCA TCTCTGCTAT GTTTGCGGAC GC - #CGCATTTG     1654     - GAGTCCAAGC TAACAACAAA TTGTTGTATG ATCTTTCGGC GGGAGCCTCA CC - #GGTACTGG     1714     - TTTATCAGTA CATGCGCGCT GATATAGGTG ACATGAGAAA GTACGCCGTC CT - #CGTGTATT     1774     - CAAAAGACGA TGCGCTCGAG ACGGACGAGC TAGTACTTCA TGTTGACATC GA - #GCACCAAC     1834     - GCATTCCCAC ATCTAGAGTA CTCCCAGTCT GATTCCGTGT TCCCAGAACC CT - #CCCTCCGA     1894     - TTTCTGTGGC GGGAGCTGAG TTGGCAGTTC TGCTATAAAC TGTCTGAAGT CA - #CTAAACGT     1954     - TTTACGGTGA ACGGGTTGTC CATCCAGCTT ACGGCTAAAA TGGTCAGTCG TG - #GAGAAATC     2014     - CACGCCAGCA GATTTACAAA TCTCTGAGGC GCCTTTGAAA CCATCTCCTA GG - #TTTTTTCG     2074     - GAAGGACTTC GGTCCGTGTA CCTCTAGCAC AACGTGCTAG TCTTAGGGTA CG - #GGTGCCCC     2134     #  2173            GTGG GGGCTCCAAA AGGAGACCA     - (2) INFORMATION FOR SEQ ID NO:7:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 264 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:     - Met Ala Leu Val Val Lys Gly Lys Val Asn Il - #e Asn Glu Phe Ile Asp     #                 15     - Leu Ser Lys Ser Glu Lys Leu Leu Pro Ser Me - #t Phe Thr Pro Val Lys     #             30     - Ser Val Met Val Ser Lys Val Asp Lys Ile Me - #t Val His Glu Asn Glu     #         45     - Ser Leu Ser Glu Val Asn Leu Leu Lys Gly Va - #l Lys Leu Ile Glu Gly     #     60     - Gly Tyr Val Cys Leu Val Gly Leu Val Val Se - #r Gly Glu Trp Asn Phe     # 80     - Pro Asp Asn Arg Arg Gly Gly Val Ser Val Cy - #s Met Val Asp Lys Arg     #                 95     - Met Glu Arg Ala Asp Glu Ala Thr Leu Gly Se - #r Tyr Tyr Thr Ala Ala     #           110     - Ala Lys Lys Arg Phe Gln Phe Lys Val Val Pr - #o Asn Tyr Gly Ile Thr     #       125     - Thr Lys Asp Ala Glu Lys Asn Ile Trp Gln Va - #l Leu Val Asn Ile Lys     #   140     - Asn Val Lys Met Ser Ala Gly Tyr Cys Pro Le - #u Ser Leu Glu Phe Val     145                 1 - #50                 1 - #55                 1 -     #60     - Ser Val Cys Ile Val Tyr Lys Asn Asn Ile Ly - #s Leu Gly Leu Arg Glu     #               175     - Lys Val Thr Ser Val Asn Asp Gly Gly Pro Me - #t Glu Leu Ser Glu Glu     #           190     - Val Val Asp Glu Phe Met Glu Asn Val Pro Me - #t Ser Val Arg Leu Ala     #       205     - Lys Phe Arg Thr Lys Ser Ser Lys Arg Gly Pr - #o Lys Asn Asn Asn Asn     #   220     - Leu Gly Lys Gly Arg Ser Gly Gly Arg Pro Ly - #s Pro Lys Ser Phe Asp     225                 2 - #30                 2 - #35                 2 -     #40     - Glu Val Glu Lys Glu Phe Asp Asn Leu Ile Gl - #u Asp Glu Ala Glu Thr     #               255     - Ser Val Ala Asp Ser Asp Ser Tyr                 260     - (2) INFORMATION FOR SEQ ID NO:8:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 2621 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (vi) ORIGINAL SOURCE:     #tomato spotted wilt virus S RNA     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:     - AGAGCAATCG TGTCAATTTT GTGTTCATAC CTTAACACTC AGTCTTACAA AT - #CATCACAT       60     - TAAGAACCTA AGAAACGACT GCGGGATACA GAGTTGCACT TTCGCACCTT GA - #GTTACATA      120     - CGGTCAAAGC ATATAACAAC TTTTACGATC ACCATGGCTT ACTCAATCAC TT - #CTCCATCG      180     - CAATTTGTGT TTTTGTCATC TGTATGGGCT GACCCTATAG AATTGTTAAA CG - #TTTGTACA      240     - AATTCGTTAG GTAACCAGTT TCAAACACAG CAAGCAAGAA CTACTGTTCA AC - #AGCAGTTC      300     - AGCGAGGTGT GGAAACCTTT CCCTCAGAGC ACCGTCAGAT TTCCTGGCGA TG - #TTTATAAG      360     - GTGTACAGGT ACAATGCAGT TTTAGATCCT CTAATTACTG CGTTGCTGGG GT - #CTTTCGAT      420     - ACTAGGAATA GAATAATCGA AGTAGAAAAC CAGCAGAATC CGACAACAGC TG - #AAACGTTA      480     - GATGCTACCC GCAGGGTAGA CGACGCTACG GTTGCAATTC GGTCTGCTAT AA - #ATAATTTA      540     - GTTAATGAAC TAGTAAGAGG TACTGGACTG TACAATCAAA ATACTTTTGA AA - #GTATGTCT      600     - GGGTTGGTCT GGACCTCTGC ACCTGCATCT TAAATCCATG GCTGTAAGTT AA - #ATTATAAA      660     - AAAGCCTATA AATATATAAA GCTTTCTTTA TCTTTATTGC TTGTGCTTGC TT - #AGTGTGTT      720     - AAATTTTAAA TAAGTGTGTT TAATTAAAGT TTGCTTTCTG TGTGTTGTGC TT - #AATAAATA      780     - ATAAAATAAC AAAAACAACG AAAACAAAAA ATAAATAAAA TAAAAATAAA AT - #AAAAATAA      840     - AATAAAATAA AAATAAAATA AAAAATAAAA AACAAAAAAC AAAAAACAAA AA - #CAAAACCC      900     - AAATTTGGCC AAATTGGTCC CTTTCGGGTC TTTTTGGTTT TTCGTTTTTT AA - #TTTTTTGT      960     - TGTTTTTATT TCATTTTTTG ATTTTATTTT ATTTTAATTT TATTTTCATT TT - #TATTTTTT     1020     - GTTTTTATGG TTTCTACTAG ACAGGAGGAA TTTGAAAGAG ATGACAAACA GA - #GAAATAAT     1080     - TATAAGTAAA GAAAGAAAAT AAACATAACA TAATTAGAAA AAGCTGGACA AA - #GCAAGATT     1140     - ATTTTGATCC TGAAGCATAC GCTTCCTTAA CCTTAGATTC TTTCTTTTTG AT - #CCCGCTTA     1200     - AATCAAGCTT TAACAAAGAT TTTGCAACTG AAATAGATTG TGGAGAAATT TT - #AATTTCTC     1260     - CTCTGGCAAA GTCTATCTTC CATGAAGGGA TTTGGATGCT GTCTAAGTAA GA - #CATAGTTT     1320     - GTGTGTTAGA TGGAAGACAT TCAAGTGTTT TTGAAAGGAA ATATTTCCTT TT - #GTAGGCAT     1380     - CTTCACTGTA ATTCAAGGTT CTTTCACCTA AATCTAACTT TCCAGGAGTT AG - #CTCAAGGT     1440     - TGTTCAAAGT GTAGATGATT ACATCTTCTT GCAAGTTAGT TGCAAAGAAC TT - #GTGCAAAG     1500     - ATGTGTGAGT TTCGAGCCAG AGCATTGGAA CCGATCCTTT GGGGTATGAA GG - #GTCATGAA     1560     - CAATGTTGTA AGGCTCCTTT AAATCAGAAA ACATCATTGA TAATTCAAAA GG - #AGCTTTGC     1620     - ATTTGCGAAT TGGGAGCTGA TGCTTGCAAA TAACAGTAAT GTTTAAAGCT GT - #CTCAACAC     1680     - TGTTATGGTT TGGAATGCAG GCAATAGATA AATAAAATGT TTTGTTTGTT TC - #ATCTCCTG     1740     - CAACCTTGAA CAATTTCTGA ATGGAAACCT GCTTCAAAAC CTTTGGAACC CT - #TAGCCAGA     1800     - GGCTCAGCTT GAAATGAGAA TCAGTGGAAG CTTGAGAGTT AGGCATGATG TT - #GTTTTCTG     1860     - CTGACATGAG CAGAGATTTC ACTGCAAGAG AATTTACAGT TCTGTTGTTG CT - #TTCAACTT     1920     - GATTGAAATT TGGCTTGAAA CTGTACAGCC ATTCATGGAC ATTTCTGTTA GG - #AGATAGAA     1980     - CATTCACTTT GCCTAAAGCC TGATTATAGC ACATCTCGAT CTTATAGGTA TG - #CTCTTTGA     2040     - CACAAGACAA AGAGCCTTTG TTTGCAGCTT CAATGTATTT GTCATTGGGA AT - #TATGTCTT     2100     - TTTCTTGGAG CTGGAATCGG TCTGTAATAT CAGATCTGTT CATGATAGAT TC - #AATAGAGT     2160     - GGAGCTGGGC AGGAGACAAA ACCTTCAAAT GACCTTGATG TTTCACTCCG TT - #AGCATTGA     2220     - CTGTATTTGA GCAAACAGAT AGTGCCAGAA CAGAGTTATC AATATTGATG CT - #AAAATCAA     2280     - TATCATCAAA AATAGGGATA TACACATGCT GAGAAAGAAA TCTCTTCTTC TT - #CACAGGGA     2340     - AGATCCCTAC TTTGCAGTAT AGCCAAAGGA CTACTTTGCT TCTTGAATCA GA - #ATACAGCT     2400     - GGGTCTGAAC TAGTTGAGAA CCAGTACCAA GTTCATGAAT CCAGTAAGAA TC - #TACAACAG     2460     - CTTTACCAGA TGCAGTTGAT CCCCAGACTG AAGCTCTTGT CTGAATGATC GA - #CTCATAAA     2520     - CACTTGAAGA CATTATGGTT ATTGGTACTG TGTTCTTATT ACAGTATTGT GA - #TTTTCTAA     2580     # 2621             AACA AAATTCTGAC ACAATTGCTC T     - (2) INFORMATION FOR SEQ ID NO:9:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 464 amino               (B) TYPE: amino acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: protein     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: Protein N - #Ss     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:     - Met Ser Ser Ser Val Tyr Glu Ser Ile Ile Gl - #n Thr Arg Ala Ser Val     #                15     - Trp Gly Ser Thr Ala Ser Gly Lys Ala Val Va - #l Asp Ser Tyr Trp Ile     #            30     - His Glu Leu Gly Thr Gly Ser Gln Leu Val Gl - #n Thr Gln Leu Tyr Ser     #        45     - Asp Ser Arg Ser Lys Val Val Leu Trp Leu Ty - #r Cys Lys Val Gly Ile     #    60     - Phe Pro Val Lys Lys Lys Arg Phe Leu Ser Gl - #n His Val Tyr Ile Pro     #80     - Ile Phe Asp Asp Ile Asp Phe Ser Ile Asn Il - #e Asp Asn Ser Val Leu     #                95     - Ala Leu Ser Val Cys Ser Asn Thr Val Asn Al - #a Asn Gly Val Lys His     #           110     - Gln Gly His Leu Lys Val Leu Ser Pro Ala Gl - #n Leu His Ser Ile Glu     #       125     - Ser Ile Met Asn Arg Ser Asp Ile Thr Asp Ar - #g Phe Gln Leu Gln Glu     #   140     - Lys Asp Ile Ile Pro Asn Asp Lys Tyr Ile Gl - #u Ala Ala Asn Lys Gly     145                 1 - #50                 1 - #55                 1 -     #60     - Ser Leu Ser Cys Val Lys Glu His Thr Tyr Ly - #s Ile Glu Met Cys Tyr     #   175     - Asn Gln Ala Leu Gly Lys Val Asn Val Leu Se - #r Pro Asn Arg Asn Val     #           190     - His Glu Trp Leu Tyr Ser Phe Lys Pro Asn Ph - #e Asn Gln Val Glu Ser     #       205     - Asn Asn Arg Thr Val Asn Ser Leu Ala Val Ly - #s Ser Leu Leu Met Ser     #   220     - Ala Glu Asn Asn Ile Met Pro Asn Ser Gln Al - #a Ser Thr Asp Ser His     225                 2 - #30                 2 - #35                 2 -     #40     - Phe Lys Leu Ser Leu Trp Leu Arg Val Pro Ly - #s Val Leu Lys Gln Val     #               255     - Ser Ile Gln Lys Leu Phe Lys Val Ala Gly As - #p Glu Thr Asn Lys Thr     #           270     - Phe Tyr Leu Ser Ile Ala Cys Ile Pro Asn Hi - #s Asn Ser Val Glu Thr     #       285     - Ala Leu Asn Ile Thr Val Ile Cys Lys His Gl - #n Leu Pro Ile Arg Lys     #   300     - Cys Lys Ala Pro Phe Glu Leu Ser Met Met Ph - #e Ser Asp Leu Lys Glu     305                 3 - #10                 3 - #15                 3 -     #20     - Pro Tyr Asn Ile Val His Asp Pro Ser Tyr Pr - #o Lys Gly Ser Val Pro     #               335     - Met Leu Trp Leu Glu Thr His Thr Ser Leu Hi - #s Lys Phe Phe Ala Thr     #           350     - Asn Leu Gln Glu Asp Val Ile Ile Tyr Thr Le - #u Asn Asn Leu Glu Leu     #       365     - Thr Pro Gly Lys Leu Asp Leu Gly Glu Arg Th - #r Leu Asn Tyr Ser Glu     #   380     - Asp Ala Tyr Lys Arg Lys Tyr Phe Leu Ser Ly - #s Thr Leu Glu Cys Leu     385                 3 - #90                 3 - #95                 4 -     #00     - Pro Ser Asn Thr Gln Thr Met Ser Tyr Leu As - #p Ser Ile Gln Ile Pro     #               415     - Ser Trp Lys Ile Asp Phe Ala Arg Gly Glu Il - #e Lys Ile Ser Pro Gln     #           430     - Ser Ile Ser Val Ala Lys Ser Leu Leu Lys Le - #u Asp Leu Ser Gly Ile     #       445     - Lys Lys Lys Glu Ser Lys Val Lys Glu Ala Ty - #r Ala Ser Gly Ser Lys     #   460     - (2) INFORMATION FOR SEQ ID NO:10:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 28 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:     #             28   CTCC TTTTGGAG     - (2) INFORMATION FOR SEQ ID NO:11:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 23 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:     #                23TACC ACT     - (2) INFORMATION FOR SEQ ID NO:12:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 45 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:     #45                TCGT GTCAATTTTG TGTTCATACC TTAAC     - (2) INFORMATION FOR SEQ ID NO:13:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 52 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:     - TTTGGATCCA GAGCAATTGT GTCAGAATTT TGTTCATAAT CAAACCTCAC TT - #      52     - (2) INFORMATION FOR SEQ ID NO:14:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:     # 20               ACTC     - (2) INFORMATION FOR SEQ ID NO:15:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:     # 20               GATG     - (2) INFORMATION FOR SEQ ID NO:16:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:     # 20               TAGT     - (2) INFORMATION FOR SEQ ID NO:17:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:     # 20               ATAC     - (2) INFORMATION FOR SEQ ID NO:18:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 176 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:     - TTTCCATGGC ATGCGACTAC ACTTGCGGTT CTAACTGCTA CTCTTCTTCA GA - #CGTTTCTA       60     - CTGCTCAAGC TGCCGGATAT AAACTTCACG AAGACGGTGA AACTGTTGGA TC - #TAATTCTT      120     - ACCCACACAA ATACAACAAC TACGAAGGTT TTGATTTCTC TGTGAGCTCT CC - #CTAC      176     - (2) INFORMATION FOR SEQ ID NO:19:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 170 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:     - GGGCCATGGT TATGTACATT CAACGAAGTT GTTACCAGAA GCACCAGTGT GA - #GTGATAAC       60     - ACCAGCATGT TGGTTGTTTT CGTTGAAGAC GACACGGTCA GCACCTGGAG AA - #GGACCAGA      120     #             170TAGAGA GGATAGGCCA TTCGTAGTAG GGAGAGCTCA     - (2) INFORMATION FOR SEQ ID NO:20:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 18 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:     #  18              AG     - (2) INFORMATION FOR SEQ ID NO:21:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 50 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:     #              50GGGGGC TCCAAAAGGA GACCACCTCT CCAAATGAAA     - (2) INFORMATION FOR SEQ ID NO:22:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 21 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:     #21                TTAA G     - (2) INFORMATION FOR SEQ ID NO:23:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 18 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:     #  18              TG     - (2) INFORMATION FOR SEQ ID NO:24:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 18 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:     #  18              GG     - (2) INFORMATION FOR SEQ ID NO:25:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 105 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:     - TTTCTGCAGA TCTTAGCCAT CCGAGTGGAC GTGCGTCCTC CTTCGGATGC CC - #AGGTCGGA       60     #                 105GC CATGCCGACC CGTAATCTTA CCACT     - (2) INFORMATION FOR SEQ ID NO:26:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 28 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:     #             28   CTCC AAATGAAA     - (2) INFORMATION FOR SEQ ID NO:27:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:     # 20               ATTT     - (2) INFORMATION FOR SEQ ID NO:28:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 23 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:     #                23TTAA ATT     - (2) INFORMATION FOR SEQ ID NO:29:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 21 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:     #21                AAAA G     - (2) INFORMATION FOR SEQ ID NO:30:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 105 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -    (iii) HYPOTHETICAL: NO     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: oligonucleot - #ide     -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:     - TTTCTGCAGA TCTTAGCCAT CCGAGTGGAC GTGCGTCCTC CTTCGGATGC CC - #AGGTCGGA       60     #                 105GC CATGCCGACC CAGAGCAATC GTGTC     __________________________________________________________________________ 

I claim:
 1. A DNA construct comprising: a sequence coding for a minus sense RNA, wherein said sequence has a complement which hybridizes to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8 under hybridization conditions involving incubation in a buffer system for about 16 hours at 55° C. and washing 3× in a buffer comprising 0.1×SSC and 0.1% SDS at 65° C. for approximately an hour each time; a promoters; and a terminator, wherein said construct is under expression control of the promoter and terminator and said minus sense RNA is replicated in a plant cell by a viral RNA dependent RNA polymerase upon viral infection and leads to the production of at least one protein or peptide.
 2. The construct of claim 1, wherein said sequence has a complement which hybridizes to SEQ ID NO:1 under hybridization conditions involving incubation in a buffer system for about 16 hours at 55° C. and washing 3× in a buffer comprising 0.1×SSC and 0.1% SDS at 65° C. for approximately an hour each time.
 3. The construct of claim 1, wherein said sequence has a complement which hybridizes to SEQ ID NO:4 under hybridization conditions involving incubation in a buffer system for about 16 hours at 55° C. and washing 3× in a buffer comprising 0.1×SSC and 0.1% SDS at 65° C. for approximately an hour each time.
 4. The construct of claim 1, wherein said sequence has a complement which hybridize to SEQ ID NO:6 under hybridization conditions involving incubation in a buffer system for about 16 hours at 55° C. and washing 3× in a buffer comprising 0.1×SSC and 0.1% SDS at 65° C. for approximately an hour each time.
 5. The construct of claim 1, wherein said sequence has a complement which hybridizes to SEQ ID NO:8 under hybridization conditions involving incubation in a buffer system for about 16 hours at 55° C. and washing 3× in a buffer comprising 0.1×SSC and 0.1% SDS at 65° C. for approximately an hour each time.
 6. The construct of claim 1 wherein said protein elicits a hypersensitive response.
 7. The construct of claim 1 wherein the protein is selected from the group consisting of plant virus, bacterial, fungal and nematode originating proteins.
 8. The construct of claim 1 wherein the protein is selected from the group consisting of ribonucleases, proteinases, ribosomal inhibitory proteins and cell wall degrading proteins.
 9. The construct of claim 1 wherein the promoter is a constitutive promoter selected from the group consisting of viral, fungal, bacterial and plant derived promoters.
 10. The construct of claim 9 wherein the promoter is a CaMV 19S, CaMV 35S, nopaline synthase, octopine synthase, or heat shock 80 promoter.
 11. Plants containing in their genome the construct of claim
 1. 12. A process of preparing virus resistant plants comprising the steps of,a) inserting into the genome of a plant cell a DNA construct which comprises a sequence coding for a minus sense RNA, a promoter, and a terminator wherein said sequence coding for a minus sense RNA has a complement which hybridizes to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8 under hybridization conditions involving incubation in a buffer system for about 16 hours at 55° C. and washing 3×in a buffer comprising 0.1× SSC and 0.1% SDS at 65° C. for approximately an hour each time, and wherein said construct is under expression control of the promoter and terminator, the minus sense RNA includes the genome or part of the genome of a plant virus, and said minus sense RNA is replicated in a plant cell by a viral RNA dependent RNA polymerase upon viral infection; b) obtaining tranformed cells; and c) regenerating from the transformed cells genetically transformed plants wherein said transformed plants contain in their genome said DNA construct and are virus resistant.
 13. The transformed virus resistant plants obtained according to claim
 12. 14. The transformed plants of claim 13 wherein the transformed plants are resistant to plant viruses selected from the group consisting of potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses and tospoviruses.
 15. The progeny of the transformed plants of claim 13 wherein said progeny contain in their genome said DNA construct and are virus resistant.
 16. The transformed plants of claim 13 wherein the plants are resistant to CMV or TSWV viral infection.
 17. A DNA construct comprising (a) a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No.4, SEQ ID No.6 and SEQ ID No.8, which encodes a minus sense RNA, (b) a promoter, and (c) a terminator wherein said promoter and terminator function in plants and the minus sense RNA is replicated in a plant cell by a viral RNA dependent RNA polymerase upon viral infection and produces at least one protein or peptide.
 18. The construct of claim 17 wherein the protein is selected from the group consisting of ribonucleases, proteinases, ribosomal inhibitory proteins and cell wall degrading proteins.
 19. The construct of claim 17 wherein the construct comprises a constitutive promoter selected from the group consisting of viral, fungal, bacterial and plant derived promoters.
 20. The construct of claim 18 wherein the promoter is a CaMV 19S, CaMV 35S, nopaline synthase, octopine synthase, or heat shock 80 promoter.
 21. Plants containing in their genome a construct according to claim
 17. 22. A process of preparing virus resistant plants comprising the steps of:a) inserting into the genome of a plant cell a DNA construct of claim 17; b) obtaining transformed plant cells; and c) regenerating from the transformed plant cells genetically transformed plants wherein said plants include in their genome the DNA construct of claim 17 and the plants are virus resistant.
 23. The construct of claim 17, wherein said minus sense RNA is encoded by SEQ ID No.1.
 24. The construct of claim 17, wherein said minus sense RNA is encoded by SEQ ID No.4.
 25. The construct of claim 17, wherein said minus sense RNA is encoded by SEQ ID No.6.
 26. The construct of claim 17, wherein said minus sense RNA is encoded by SEQ ID No.8. 